The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...
Explore how political divisiveness impacts mental health and amplifies high-functioning depression, and discover strategies ...
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...
A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
The therapy scored a phase 2 win last year by showing that it significantly reduced depression severity among adults with major depressive disorder (MDD) who haven’t benefited from at least one ...